Patents Represented by Attorney Robins & Pasternak

Find this attorney in the Justia Lawyer Directory

  • Eliciting HCV-specific antibodies
    Patent number: 7329408
    Abstract: Described herein is a method of eliciting antibodies and neutralizing of binding antibodies against a hepatitis C virus (HCV) E1E2 or E2 antigen using HCV E2 or HCV E1E2 polypeptides and/or HCV E2 or E1E2 polynucleotides. Elicitation of anti-E2 antibodies and anti-E2 NOB antibodies can be used, inter alia, to provide model systems to optimize anti-E2 antibody responses and/or anti-E2 NOB antibody responses to HCV and to provide prophylactic or therapeutic treatment against HCV infection.
    Type: Grant
    Filed: December 1, 2000
    Date of Patent: February 12, 2008
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Michael Houghton, Mark Selby, Sergio Abrignani, Jens Martin Heile, Derek O'Hagan
  • Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor
    Patent number: 7329640
    Abstract: The present invention provides methods of treating hemorrhagic fevers where selective inhibitors of fVIIa/TF are used as a treatment for hemorrhagic fevers and have therapeutic effects which include ameliorating and/or preventing coagulopathy and inflammatory responses. These inhibitors include certain proteins which are part of a family termed Nematode-Extracted Anticoagulant Proteins (“NAPs”). Other inhibitors include Tissue Factor Pathway Inhibitor (“TFPI”) and TFPI analogs.
    Type: Grant
    Filed: September 12, 2006
    Date of Patent: February 12, 2008
    Assignee: Dendreon Corporation
    Inventor: George P. Vlasuk
  • Hepatitis C virus E2 binding protein
    Patent number: 7320875
    Abstract: HCV assays are described. The assays utilize a 24 kd protein capable of binding the E2 envelope protein of hepatitis C virus (HCV), or functionally equivalent variants or fragments of the 24 kd protein.
    Type: Grant
    Filed: March 9, 2006
    Date of Patent: January 22, 2008
    Assignee: Chiron S.r.l.
    Inventor: Sergio Abrignani
  • Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and DNA coding for the same
    Patent number: 7320880
    Abstract: A gene encoding a polypeptide having an activity to support proliferation or survival of hematopoietic stem cells or hematopoietic progenitor cells is isolated by comparing expressed genes between cells which support proliferation or survival of hematopoietic stem cells or hematopoietic progenitor cells which do not support the proliferation or survival. Proliferation or survival of hematopoietic stem cells or hematopoietic progenitor cells is supported by using stromal cells in which the isolated gene is expressed or a gene product of the isolated gene.
    Type: Grant
    Filed: June 11, 2002
    Date of Patent: January 22, 2008
    Assignees: Nuvelo, Inc., Kirin Beer Kabushiki Kaisha
    Inventors: Mitsuo Nishikawa, Radoje T. Drmanac, Ivan Lobal, Y. Tom Tang, Juhi Lee, Birgit Stache-Crain
  • Stem cell growth factor-like polypeptides
    Patent number: 7319141
    Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human stem cell growth factor-like protein. These polynucleotides comprise nucleic acid sequences isolated from cDNA libraries from human testis cells (Hyseq clone identification numbers 2880984 and 2881695), from human fetal skin (Hyseq clone identification number 15375176), adult spleen (Hyseq clone identification number 14856094), and human endothelial cells (Hyseq clone identification numbers 13804756, 13687487, 13804756). Other aspects of the invention include vectors containing processes for producing novel human stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides.
    Type: Grant
    Filed: October 19, 2004
    Date of Patent: January 15, 2008
    Assignees: Kirin Beer Kabushiki Kaisha, Nuvelo, Inc.
    Inventors: Y. Tom Tang, Ivan Labat, Radoje T. Drmanac, Nancy K. Mize, Mitsuo Nishikawa, Cheng-Chi Chao
  • Polynucleotides encoding stem cell growth factor-like polypeptides
    Patent number: 7317099
    Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted stem cell growth factor-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA libraries prepared from human fetal liver spleen, ovary, adult brain, lung tumor, spinal cord, cervix, ovary, endothelial cells, umbilical cord, lymphocyte, lung fibroblast, fetal brain, and testis. Other aspects of the invention include vectors containing processes for producing novel human secreted stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides.
    Type: Grant
    Filed: December 23, 2000
    Date of Patent: January 8, 2008
    Assignee: Kirin Pharma Kabushiki Kaisha
    Inventors: Ivan Labat, Y. Tom Tang, Radoje T. Drmanac, Chenghua Liu, Juhi Lee, Nancy K. Mize, John Childs, Cheng-Chi Chao
  • Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases
    Patent number: 7316911
    Abstract: A method is provided for the localized intravascular administration of a fibrinolytic metalloproteinase to a human subject in amounts that are both safe and effective to lyse an occluding fibrin-containing blood clot, while also avoiding the neutralizing effects of ?2-macroglobulin in the circulating blood. A method is also provided for the treatment of a blood clot in, around or attached to an indwelling vascular access device. A method for restoring patency and function of an indwelling vascular access device is also provided.
    Type: Grant
    Filed: October 13, 2005
    Date of Patent: January 8, 2008
    Assignee: Amgen, Inc.
    Inventor: Christopher F. Toombs
  • Methods of treating peripheral arterial occlusions
    Patent number: 7314728
    Abstract: A method is provided for the localized intravascular administration of a fibrinolytic metalloproteinase to a human subject in amounts that are both safe and effective to lyse an occluding fibrin-containing blood clot, while also avoiding the neutralizing effects of ?2-macroglobulin in the circulating blood. A method is also provided for the treatment of a blood clot in, around or attached to an indwelling vascular access device. A method for restoring patency and function of an indwelling vascular access device is also provided.
    Type: Grant
    Filed: October 13, 2005
    Date of Patent: January 1, 2008
    Assignee: Amgen, Inc.
    Inventor: Christopher F. Toombs
  • Pharmaceutical compositions of fibrinolytic agent
    Patent number: 7311908
    Abstract: Frozen and lyophilized compositions for a metalloproteinase fibrinolytic agent (fibrolase or NAT), a method for preparing the lyophilized composition, and a kit and method for reconstituting the lyophilized composition are described herein.
    Type: Grant
    Filed: June 29, 2006
    Date of Patent: December 25, 2007
    Assignee: Amgen, Inc.
    Inventors: Brent S. Kendrick, Brian A. Peterson
  • Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
    Patent number: 7306801
    Abstract: Methods for treating a subject with a cancer that is characterized by overexpression of HER2 receptor protein using a combination of interleukin-2 (IL-2) or variant thereof and at least one anti-HER2 antibody or fragment thereof are provided. These anti-tumor agents are administered as two separate pharmaceutical compositions, one containing IL-2 (or variant thereof), the other containing at least one anti-HER2 antibody (or fragment thereof), according to a dosing regimen. Administering of these two agents together potentiates the effectiveness of the anti-HER2 antibody alone, resulting in a positive therapeutic response that is improved with respect to that observed with this anti-tumor agent.
    Type: Grant
    Filed: May 14, 2001
    Date of Patent: December 11, 2007
    Assignees: Health Research, Inc., ARCH Development
    Inventors: Michael A. Caligiuri, Neal J. Meropol, Richard L. Schilsky
  • Method for treating multi-drug resistant tumors
    Patent number: 7303760
    Abstract: Methods for administering mitomycin C to a multi-drug resistant cell and for reducing the toxicity of the compound are described. In the methods, mitoymic C is provided in the form of a prodrug conjugate, where the drug is linked to a hydrophobic moiety, such as a lipid, through a cleavable dithiobenzyl linkage. The dithiobenzyl linkage is susceptible to cleavage by mild thiolysis, resulting in release of mitomycin C in its original form. The linkage is stable under nonreducing conditions. The prodrug conjugate can be incorporated into liposomes for administration in vivo and release of mitomycin C in response to endogenous in vivo reducing conditions or in response to administration of an exogenous reducing agent.
    Type: Grant
    Filed: November 14, 2003
    Date of Patent: December 4, 2007
    Assignees: Alza Corporation, Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Samuel Zalipsky, Alberto Gabizon
  • Methods and compositions for interaction trap assays
    Patent number: 7297491
    Abstract: The present invention provides methods and compositions for interaction trap assays for detecting protein-protein, protein-DNA, or protein-RNA interactions. The methods and compositions of the invention may also be used to identify agents which may agonize or antagonize a protein-protein, protein-DNA, or protein-RNA interactions. In certain embodiments, the interaction trap system of the invention is useful for screening libraries with greater than 107 members. In other embodiments, the interaction trap system of the invention is used in conjunction with flow cytometry. The invention further provides a means for simultaneously screening a target protein or nucleic acid sequence for the ability to interact with two or more test proteins or nucleic acids.
    Type: Grant
    Filed: August 10, 2004
    Date of Patent: November 20, 2007
    Assignee: Massachusetts Institute of Technology
    Inventors: J. Keith Joung, Jeffrey Miller, Carl O. Pabo
  • Immunogenic detoxified mutant LT-A toxin
    Patent number: 7291588
    Abstract: An immunogenic detoxified protein is provided which comprises the amino acid sequence of subunit A of an E. coli heat labile toxin (LT-A) or a fragment thereof in which at least amino acid Ala-72 of the A subunits mutated, preferably by substitution with Arg. The toxoid is useful as vaccine against an enterotoxigenic strain of E. coli and is produced by recombinant DNA means by site-directed mutagenesis. It is also an effective adjuvant.
    Type: Grant
    Filed: November 25, 2002
    Date of Patent: November 6, 2007
    Assignee: Chiron Srl
    Inventors: Mariagrazia Pizza, Marzia Monica Giuliani, Rino Rappuoli
  • antigens, antibodies thereto and diagnostic and therapeutic compositions thereof
    Patent number: 7288621
    Abstract: Cloning and expression of genes encoding C. parvum antigenic polypeptides are described as are antibodies that recognize epitopes on these polypeptides. The antigenic polypeptides and antibodies thereto can be used in therapeutic compositions for the prevention and treatment of C. parvum infections, as well as in diagnostic methods for determining the presence of C. parvum infections.
    Type: Grant
    Filed: September 23, 2004
    Date of Patent: October 30, 2007
    Assignee: University of Manitoba
    Inventor: J. Neil Simonsen
  • Regulated gene expression in plants
    Patent number: 7285416
    Abstract: A method is provided of regulating transcription in a plant cell from a DNA sequence comprising a target DNA operably linked to a coding sequence, which method comprises introducing an engineered zinc finger polypeptide in said plant cell which polypeptide binds to the target DNA and modulates transcription of the coding sequence.
    Type: Grant
    Filed: July 10, 2002
    Date of Patent: October 23, 2007
    Assignees: Gendaq Limited, The Rockefeller University
    Inventors: Yen Choo, Christopher Graeme Ullman, Nam-Hai Chua, Juan Pablo Sanchez
  • Process for manufacture of Nematode-extracted Anticoagulant Protein (NAP)
    Patent number: 7279309
    Abstract: The present invention provides a process for manufacture of purified Nematode-extracted Anticoagulant Proteins (NAPs), wherein the NAP manufactured by the claimed process method is a NAP drug substance that can be formulated as a NAP drug product. The present invention provides NAP drug substances and NAP drug products manufactured by the process disclosed herein. In one embodiment, the present invention provides a process for manufacture of rNAPc2/proline drug substance and rNAPc2/proline drug product, and provides rNAPc2/proline drug substance manufactured by the process disclosed herein.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: October 9, 2007
    Assignee: Dendreon Corporation
    Inventors: Christine B. Mendoza, John Lidell, David Moss
  • Zinc finger proteins for DNA binding and gene regulation in plants
    Patent number: 7273923
    Abstract: Disclosed herein are modified plant zinc finger proteins; compositions comprising modified plant zinc finger proteins and methods of making and using modified plant zinc finger proteins. The modified plant zinc finger proteins, in contrast to naturally-occurring plant zinc finger proteins, have a binding specificity that is determined by tandem arrays of modular zinc finger binding units.
    Type: Grant
    Filed: January 22, 2002
    Date of Patent: September 25, 2007
    Assignee: Sangamo Biosciences, Inc.
    Inventors: Andrew Jamieson, Guofu Li
  • Immunization of dairy cattle with GapC protein against infection
    Patent number: 7273930
    Abstract: The GapC plasmin binding protein genes of Streptococcus dysgalactiae (S. dysgalactiae), Streptococcus agalactiae (S. agalactiae), Streptococcus uberis (S. uberis), Streptococcus parauberis (S. parauberis), and Streptococcus iniae (S. iniae) are described, as well as the recombinant production of the GapC proteins therefrom. Also described is the use of the GapC proteins from those species in vaccine compositions to prevent or treat bacterial infections in general, and mastitis in particular.
    Type: Grant
    Filed: December 6, 2004
    Date of Patent: September 25, 2007
    Assignee: The University of Saskatchewan
    Inventors: Alexandra J. Bolton, Jose Perez-Casal, Michael Fontaine, Andrew A. Potter
  • Methods for treating neuropathic pain by administering IL-10 polypeptides
    Patent number: 7261882
    Abstract: Methods of treating pain by delivery of anti-inflammatory cytokines, proinflammatory cytokine antagonists, and agents that act to reduce or prevent proinflammatory cytokine actions, to the nervous system are described. These agents can be delivered using gene therapy techniques. Alternatively, the agents can be delivered in protein compositions.
    Type: Grant
    Filed: December 18, 2003
    Date of Patent: August 28, 2007
    Assignee: Reagents of the University of Colorado
    Inventor: Linda May Rothblum Watkins
  • Methods for producing preparations of recombinant AAV virions substantially free of empty capsids
    Patent number: 7261544
    Abstract: Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.
    Type: Grant
    Filed: May 21, 2004
    Date of Patent: August 28, 2007
    Assignee: Genzyme Corporation
    Inventors: Guang Qu, John Fraser Wright